Arpeggio Bio

Arpeggio Bio develops drugs targeting transcription factors using AI…

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Category
Analytics
Pricing
freemium
Difficulty
beginner

Y Combinator batch: Summer 2019

Directory records are starting points for research. Check the official website for current features, pricing and availability. A catalog sync is not a hands-on product review.

Official website

Features

  • AI-Powered
  • API Access

Industries

  • Healthcare